

Use code:  
MB19News1  
to save  
\$125!

# Miami Breast Cancer CONFERENCE®

# update

## A Message From the Chair

*Patrick I. Borgen, MD*

It's hard to believe it's already been 7 months since the last **Miami Breast Cancer Conference®**. Seven months since we last gathered at the Fontainebleau in Miami Beach for 4 days of learning and celebrating the latest in breast cancer research.

2018 has already been quite the year for new data, most of which has revolved around one theme: the de-escalation of therapy. At the most recent meeting in Chicago we first heard the latest results from trials such as **TAILORx** and **PERSPEHONE**, which are already changing the way we treat patients with early-stage breast cancer.

As exciting a time this is, with every new trial comes new questions. How the latest data impacts your practice and your patients requires a careful understanding of new data, that takes a multidisciplinary perspective into account.

The **Miami Breast Cancer Conference®** is a meeting uniquely positioned to provide that perspective. With faculty and learners of complex and differing backgrounds, someone in Miami will always be able to answer your questions and help with your most difficult cases. Whether it was first reported at a major meeting or the supplement of a journal, what you need to know, and how to use it, will be presented at Miami.

I can't wait to see you there!



**Patrick I. Borgen, MD**  
Chairman, Department of Surgery  
Maimonides Hospital  
Director, Brooklyn Breast  
Cancer Program  
Brooklyn, NY



"HEAR IT ON FRIDAY...  
....USE IT ON MONDAY."



**JOIN US NEXT YEAR!**

**March 7-10, 2019 • Miami Beach, FL**

## Benefits of Attending

- Network with your peers and the leading experts
- Challenge world-renowned thought leaders with your toughest questions
- Learn how to apply the latest evidence, therapies, and strategies in your practice and look forward to 2019.

**Registration starting  
at \$499!**

For more information visit us online now at...

[gotoper.com/go/MB19NEWS1](http://gotoper.com/go/MB19NEWS1)



## The Latest in Therapy De-escalation

### PERSEPHONE Trial Offers New Options for HER2+ Disease


For patients with HER2-positive disease, the results presented from the phase III **PERSEPHONE** trial showed patients with early-stage breast cancer could receive shorter treatment to achieve the same outcome. Researchers demonstrated a 6-month course of adjuvant trastuzumab was noninferior for disease-free survival (DFS) compared with the standard 12-month schedule. Overall, the 4-year DFS rate was 89.8% with 12 months of trastuzumab compared with 89.4% for patients on the 6-month arm. A full debrief on the results from this trial and how they inform your practice, will be presented at this year's meeting.



### How TAILORx is Reshaping Treatment

Perhaps the biggest news out of ASCO came from the phase III **TAILORx** study, which showed adjuvant endocrine therapy (ET) alone was noninferior to adjuvant ET in combination with chemotherapy for patients with hormone receptor (HR)-positive, HER2-negative, early-stage breast cancer. Patients for whom noninferiority was demonstrated had node-negative disease and an intermediate risk score for distant recurrence. Nine-year rates were similar for patients receiving ET alone and ET plus chemo, including invasive DFS (83.3% vs. 84.3%), and overall survival (93.9% vs. 93.8%). The results from TAILORx, if implemented, may save thousands of women with breast cancer from overtreatment.

**TAILORx study lead and lead author, Joseph A. Sparano, MD, from Albert Einstein College of Medicine, will be at Miami Breast and leading the conversation on therapy de-escalation!**




## ANNOUNCING THIS YEAR'S KEYNOTE SPEAKER

Dr. Gregory Stock

Dr. Gregory Stock is a biotech entrepreneur, bioethicist, and best-selling author of books such as *Redesigning Humans: Our Inevitable Genetic Future* and *The Book of Questions*. Dr. Stock, who currently serves as the Co-Director of the Mount Sinai Precision Wellness Center, is one of the leading authorities on the role of genomics in medicine. This year, at the **Miami Breast Cancer Conference®**, Dr. Stock will be delivering the keynote address, exploring the role of genomics in breast cancer and our everyday lives.

This year's keynote lecture will take place on Saturday, March 9



## Agenda Highlights

### Friday, March 8, 2019

#### The US Opioid Crisis and Breast Cancer

*Patrick I. Borgen, MD*

#### TAILORx and the De-escalation of Therapy

*Joseph A. Sparano, MD*

#### Nontraditional Genetic Counseling: Solving the Challenge of the Undetected Carrier

*Pat W. Whitworth, MD*

#### CDK4/6 Inhibitors - Where Are We, and What's Next?

*Debu Tripathy, MD*

#### Update From ESMO: Immunotherapy in Breast Cancer

*Elizabeth Mittendorf, MD, PhD, & Hope S. Rugo, MD, FASCO*

### Saturday, March 9, 2019

#### State-of-the-Art Approach to MRI in Breast Cancer

*Elizabeth Morris, MD, FACR, FSBI, FISMRM*

#### Controversies in the Optimal Management of HER2+ Breast Cancer

*Mark D. Pegram, MD*

#### Surgery for the Primary in De Novo Stage IV Disease

*Tari A. King, MD*

#### Breast Cancer in Pregnancy and in Younger Women

*Ann H. Partridge, MD, MPH*

#### Medical Crossfire®: Optimal De-escalation in Patients Undergoing BCT for pN0 Breast Cancer: PBI or Omission?

*Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; and Frank A. Vicini, MD, FACR, FABS, FASTRO;*

#### Keynote Address

*Gregory Stock, PhD*

### Sunday, March 10, 2019

#### Rare Breast Cancers

*David M. Euhus, MD, FACS*

#### Physician Burnout: An Action-Oriented Roundtable Discussion

*Patrick I. Borgen, MD; Anees B. Chagpar, MD, MSc, MPH, MA, MBA, FACS, FRCSC; Kelly K. Hunt, MD; and, Pat W. Whitworth, MD*

#### The Art and Science of Survivorship Planning and Management

*Ann H. Partridge, MD, MPH*

## Meet the Program Chairs:



#### Patrick I. Borgen, MD

Chair, Department of Surgery  
Maimonides Medical Center  
Brooklyn, NY  
Program Chair, **Miami Breast Cancer Conference®**

**Talks at Miami Breast:** The US Opioid Crisis and Breast Cancer (Friday); **Medical Crossfire®:** Optimal De-escalation in Patients Undergoing BCT for pN0 Breast Cancer: PBI or Omission? (Saturday); Physician Burnout: An Action-Oriented Roundtable Discussion (Sunday)



#### Elizabeth Mittendorf, MD, PhD

Robert and Karen Hale Distinguished Chair in Surgical Oncology  
Director, Breast Immuno-Oncology Program  
Dana-Farber/Brigham and Women's Cancer Center  
Boston, MA  
Program Co-Chair, **Miami Breast Cancer Conference®**

#### Talks at Miami Breast:

Immunotherapy in Breast Cancer (Friday)



#### Hope S. Rugo, MD, FASCO

Professor of Medicine  
Director, Breast Oncology and Clinical Trials Education  
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center  
San Francisco, CA  
Program Co-Chair, **Miami Breast Cancer Conference®**

#### Talks at Miami Breast:

Immunotherapy in Breast Cancer (Friday)



#### Debu Tripathy, MD

Professor and Chair  
Department of Breast Medical Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, TX  
Program Co-Chair, **Miami Breast Cancer Conference®**

#### Talks at Miami Breast:

CDK4/6 Inhibitors: Where Are We, and What's Next? (Friday)

**Miami**  
**Breast Cancer**  
CONFERENCE®  
*update*

2 Clarke Drive, Suite 110  
Cranbury, NJ 08512

Phone: (888) 949-0045  
E-mail: [info@gotoper.com](mailto:info@gotoper.com)

REGISTER TODAY, USING CODE **MB19NEWS1** TO SAVE \$125



TWO WAYS TO REGISTER



Online

Visit us online at  
[gotoper.com/go/MBCC19BRO](http://gotoper.com/go/MBCC19BRO)

or



Call

1-609-378-3701

For any other question email us at:  
[info@gotoper.com](mailto:info@gotoper.com)

For more information visit us online now at...  
[gotoper.com/go/MB19NEWS1](http://gotoper.com/go/MB19NEWS1)

